St. Jude Medical (STJ) Scheduled to Post Quarterly Earnings on Wednesday
St. Jude Medical (NYSE:STJ) is scheduled to release its Q313 earnings data on Wednesday, October 16th. Analysts expect St. Jude Medical to post earnings of $0.89 per share and revenue of $1.32 billion for the quarter. St. Jude Medical has set its Q3 guidance at $0.88-0.90 EPS and its FY13 guidance at $3.70-3.73 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.
St. Jude Medical (NYSE:STJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $0.96 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.94 by $0.02. The company had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the prior year, the company posted $0.86 earnings per share. The company’s quarterly revenue was down .5% on a year-over-year basis. On average, analysts expect St. Jude Medical to post $3.72 EPS for the current fiscal year and $3.97 EPS for the next fiscal year.
St. Jude Medical (NYSE:STJ) opened at 56.03 on Tuesday. St. Jude Medical has a 1-year low of $30.25 and a 1-year high of $57.17. The stock has a 50-day moving average of $53.22 and a 200-day moving average of $47.98. The company has a market cap of $16.091 billion and a price-to-earnings ratio of 26.06.
STJ has been the subject of a number of recent research reports. Analysts at Cowen and Company upgraded shares of St. Jude Medical from an “underperform” rating to a “market perform” rating in a research note to investors on Monday. They now have a $53.00 price target on the stock, up previously from $38.00. On a related note, analysts at Wedbush raised their price target on shares of St. Jude Medical from $57.00 to $60.00 in a research note to investors on Thursday, October 10th. They now have an “outperform” rating on the stock. Finally, analysts at Barclays raised their price target on shares of St. Jude Medical from $57.00 to $61.00 in a research note to investors on Monday, September 23rd. They now have an “overweight” rating on the stock. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $48.24.
In other St. Jude Medical news, Insider Denis Gestin sold 137,000 shares of St. Jude Medical stock on the open market in a transaction dated Friday, October 4th. The stock was sold at an average price of $55.25, for a total value of $7,569,250.00. Following the sale, the insider now directly owns 6,257 shares of the company’s stock, valued at approximately $345,699. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.